Evidence & regulatory context
- Mechanism
- Non-steroidal anti-inflammatory drug, preferential COX-2 inhibitor (from ChEMBL compound record and ATC M01AC06; get_mechanism was not called this run).
- Target
- Not recorded
- Injury models
- Spinal cord injury · Other
- Reported indication
- Not recorded
- First approval
- 2000
- Development stage
- Not recorded
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Mobic; Anjeso; Vivlodex; Metacam; N-1539; Qmiiz ODT
- Note
- Not recorded
Clinical trials 5
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Randomized, Open-label, Controlled Trial to Assess the Clinical Efficacy and Safety of Meloxicam Suspension 0.25 mg/kg/Day Once a Day, Versus Diclofenac 1 mg/kg/Day Twice a Day or Nimesulide 4 mg/kg/Day Twice a Day, for Five Days in the Treatment of Patients With Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis
Pharyngitis
Enrolment: 128 · Results not recorded
Parallel-group Active Comparator, Double-blind, Randomized, Phase III Study to Assess Safety, Efficacy of Glucosamine Sulfate Plus Meloxicam vs Glucosamine Sulfate Plus Chondroitin Sulfate Primary Symptomatic Knee Osteoarthritis Treatment
Knee Osteoarthritis
Enrolment: 0 · Results not recorded
A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis
Arthritis, Juvenile Rheumatoid
Enrolment: 180 · Results not recorded
Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea
Dysmenorrhea
Enrolment: 337 · Results not recorded
Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
Arthritis, Rheumatoid
Enrolment: 9984 · Results not recorded
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatSpinal cord injuryCompressionn = 24 rats in total, randomly divided into 4 groupsTranscutaneous laser irradiation; meloxicam route not statedPhotobiomodulation 810 nm, 200 mW, 8 s per session; meloxic…Treatment started after injury induction
Model: Compression injury of the T8-T9 spinal cord segment induced with a Fogarty embolectomy catheter
Four weeks after injury, BBB scores were significantly higher in all three treatment groups than in the control group, with no significant differences between treatment groups and no significant histological differences between any of the four groups.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
RatOtherWistarMalen = 39 rats, 13 per groupIntraperitoneal injectionGroup A dosed daily for the first 10 postoperative days; group B dosed from pos…
Model: Acute rotator cuff tear created surgically and immediately repaired
Meloxicam given between days 11 and 20 after repair lowered mean maximal load at 3 weeks versus saline controls (P=0.02) and versus early dosing (P=0.05), with lower stiffness than group A (P=0.05); histology showed no apparent differences in cellularity, vascularity, healing or collagen orientation
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
